GEN Secures BEBO Foundation Approval for Phase II PD Trial

Why It Matters

The trial tackles mitochondrial dysfunction, a core driver of neurodegeneration, offering a potential first‑in‑class disease‑modifying treatment for Parkinson’s and reshaping the neuro‑therapeutics market.

Key Takeaways

• BEBO Foundation grants ethical clearance for Phase II trial
• Trial named SHEPHERD starts patient enrolment April 2026
• SUL‑238 targets mitochondrial complex I/IV activation
• Study uses 31P‑MRS to measure high‑energy phosphates
• Single‑centre, double‑blind, placebo‑controlled design ensures rigor

Pulse Analysis

Parkinson’s disease remains one of the most pressing unmet medical needs, with current therapies limited to symptom management. Emerging research points to mitochondrial dysfunction as a pivotal factor in neuronal loss, prompting biotech firms to explore bioenergetic restoration. GEN Pharmaceuticals’ SUL‑238, a hibernation‑inspired small molecule, activates mitochondrial complexes I and IV, enhancing cellular energy production across pre‑clinical models of cardiovascular, renal, and neurodegenerative disorders. By licensing the compound from Sulfateq, GEN positions itself at the forefront of a new therapeutic class aimed at the disease’s biological root.

The SHEPHERD Phase II trial adopts a rigorous design: a randomised, double‑blind, placebo‑controlled protocol conducted at a single site in Groningen. Participants with early, untreated Parkinson’s will receive daily SUL‑238 or placebo for 28 days, with bi‑weekly clinic visits and a post‑treatment follow‑up. The study’s primary endpoint leverages 31P‑magnetic resonance spectroscopy to quantify high‑energy phosphates, providing a direct, non‑invasive readout of mitochondrial function. Coupled with comprehensive safety monitoring and symptom diaries, the trial aims to generate robust proof‑of‑concept data that could accelerate regulatory pathways.

If SUL‑238 demonstrates meaningful improvements in mitochondrial bioenergetics and a favorable safety profile, the implications extend beyond Parkinson’s. A successful outcome would validate mitochondrial modulation as a viable strategy for neurodegeneration, potentially unlocking applications in Alzheimer’s, ALS, and other disorders. Investors and pharmaceutical partners are likely to view the data as a catalyst for further funding and collaborative development, positioning GEN Pharmaceuticals as a key player in the next wave of disease‑modifying neuro‑therapies.